Two types of procoagulant platelets are formed upon physiological activation and are controlled by integrin αiIbβ 3

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 10, 2012, Pages 2475-2483

  Topalov, Nikolay N ^a   Yakimenko, Alena O ^b   Canault, Matthias ^c,d,e   Artemenko, Elena O ^a   Zakharova, Natalia V ^a   Abaeva, Anastasia A ^a   Loosveld, Marie ^c,d,e   Ataullakhanov, Fazoil I ^a,b,f,g,h   Nurden, Alan T ⁱ   Alessi, Marie Christine ^c,d,e   Panteleev, Mikhail A ^a,b,f,g  

^a CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^b HemaCore LLC   (Russian Federation)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CNRS   (France)

^e TIMONE HOSPITAL   (France)

^f NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^g MOSCOW STATE UNIVERSITY   (Russian Federation)

^h Federal Research and Clinical Center of Pediatric Hematology   (Russian Federation)

ⁱ Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

adhesion molecules; phosphatidylserine; platelets; signal transduction

Indexed keywords

FIBRINOGEN; INTEGRIN; INTEGRIN ALPHAIIBBETA3; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM SIGNALING; CYTOPLASM; GLANZMANN DISEASE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

BLOOD COAGULATION; BLOOD PLATELETS; CALCIUM; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PHOSPHATIDYLSERINES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBASTHENIA; THROMBOSIS;

EID: 84866615497     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.253765     Document Type: Article

References (37)

1. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem. 1978;253:6908-6916.
2. Heemskerk JW, Siljander PR, Bevers EM, Farndale RW, Lindhout T. Receptors and signalling mechanisms in the procoagulant response of platelets. Platelets. 2000;11:301-306.
3. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185-2192.
4. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood. 2010;116:2011-2018.
5. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost. 2011;9(Suppl 1): 76-91.
6. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a fow cytometry study showing a role for free sulf-hydryl groups. Blood. 1993;81:2554-2565.
7. Munnix IC, Cosemans JM, Auger JM, Heemskerk JW. Platelet response heterogeneity in thrombus formation. Thromb Haemost. 2009;102:1149-1156.
8. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol. 2005;25:861-866.
9. Panteleev MA, Ananyeva NM, Greco NJ, Ataullakhanov FI, Saenko EL. Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex. J Thromb Haemost. 2005;3:2545-2553.
10. Keuren JF, Wielders SJ, Ulrichts H, Hackeng T, Heemskerk JW, Deckmyn H, Bevers EM, Lindhout T. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-acti-vated receptor-1. Arterioscler Thromb Vasc Biol. 2005;25:1499-1505.
11. London FS, Marcinkiewicz M, Walsh PN. PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium. Biochemistry. 2006;45: 7289-7298.
12. Kulkarni S, Jackson S P. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem. 2004;279:30697-30706.
13. Topalov NN, Kotova YN, Vasil'ev SA, Panteleev MA. Identifcation of signal transduction pathways involved in the formation of platelet sub-populations upon activation. Br J Haematol. 2012;157:105-115.
14. Jobe SM, Wilson KM, Leo L, Raimondi A, Molkentin JD, Lentz SR, Di Paola J. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111:1257-1265.
15. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol. 2005;25:467-471.
16. Brooks MB, Catalfamo JL, Friese P, Dale GL. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mito-chondrial depolarization. J Thromb Haemost. 2007;5:1972-1974.
17. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415:175-179.
18. Kotova YN, Ataullakhanov FI, Panteleev MA. Formation of coated platelets is regulated by the dense granule secretion of adenosine 5'diphosphate acting via the P2Y12 receptor. J Thromb Haemost. 2008;6:1603-1605.
19. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phe-notypic variability, and mouse models. Blood. 2011;118:5996-6005.
20. Byzova TV, Vlasik TN, Mazurov AV. [Inhibition of platelet aggregation with monoclonal antibodies to the glycoprotein IIb-IIIa complex]. Biull Eksp Biol Med. 1994;118:402-405.
21. Mazurov AV, Pevzner DV, Antonova OA, Byzova TV, Khaspekova SG, Semenov AV, Vlasik TN, Samko AN, Staroverov II, Ruda MY. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets. 2002;13:465-477.
22. Ramjee MK. The use of fuorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation. Anal Biochem. 2000;277:11-18.
23. Robert P, Canault M, Farnarier C, Nurden A, Grosdidier C, Barlogis V, Bongrand P, Pierres A, Chambost H, Alessi MC. A novel leukocyte adhesion defciency III variant: kindlin-3 defciency results in integrin-and nonintegrin-related defects in different steps of leukocyte adhesion. J Immunol. 2011;186:5273-5283.
24. Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis. 2006;1:46.
25. Rukoyatkina N, Begonja AJ, Geiger J, Eigenthaler M, Walter U, Gambaryan S. Phosphatidylserine surface expression and integrin alpha IIb beta 3 activity on thrombin/convulxin stimulated platelets/particles of different sizes. Br J Haematol. 2009;144:591-602.
26. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112:3011-3025.
27. Dachary-Prigent J, Pasquet JM, Fressinaud E, Toti F, Freyssinet JM, Nurden AT. Aminophospholipid exposure, microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a patient with Scott syndrome: a study using physiologic agonists and local anaesthetics. Br J Haematol. 1997;99:959-967.
28. Matsumoto Y, Marukawa K, Okumura H, Adachi T, Tani T, Kimura Y. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses. Thromb Res. 1999;95:19-29.
29. Razmara M, Hu H, Masquelier M, Li N. Glycoprotein IIb/IIIa blockade inhibits platelet aminophospholipid exposure by potentiating translocase and attenuating scramblase activity. Cell Mol Life Sci. 2007;64:999-1008.
30. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest. 1996;98:863-874.
31. Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 1998;90:247-258.
32. Dicker IB, Pedicord DL, Seiffert DA, Jamieson GA, Greco NJ. Both the high affnity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity. Thromb Haemost. 2001;86:1065-1069.
33. Jones ML, Harper MT, Aitken EW, Williams CM, Poole AW. RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation. J Thromb Haemost. 2010;8:567-576.
34. Hamilton SF, Miller MW, Thompson CA, Dale GL. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. J Lab Clin Med. 2004;143:320-326.
35. Shcherbina A, Cooley J, Lutskiy MI, Benarafa C, Gilbert GE, Remold-O'Donnell E. WASP plays a novel role in regulating platelet responses dependent on alphaIIbbeta3 integrin outside-in signalling. Br J Haematol. 2010;148:416-427.
36. Goschnick MW, Lau LM, Wee JL, Liu YS, Hogarth PM, Robb LM, Hickey MJ, Wright MD, Jackson DE. Impaired "outside-in" integrin alphaIIbbeta3 signaling and thrombus stability in TSSC6-defcient mice. Blood. 2006;108:1911-1918.
37. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in alphaI-Ibbeta3 signalling and platelet function. Nature. 1999;401:808-811.